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Abstract 
The present article illustrates how the main actors in global health governance (GHG)—
governments, nongovernmental organizations (NGOs), intergovernmental organizations 
(IOs), and transnational pharmaceutical companies (TNPCs)—have been interacting and, 
as a result, modifying the global health architecture in general and AIDS treatment in par-
ticular. Using the concept of “power types” (Keohane/Martin) and “interfaces” (Norman 
Long), the authors examine the conflicts among major GHG actors that have arisen sur-
rounding the limited access to medicines for fighting HIV/AIDS basically as a result of the 
Agreement on Trade Related Intellectual Property Rights (TRIPS), in force since 1995. They 
then analyze the efforts of Brazil and South Africa to obtain fast and low-cost access to 
antiretroviral medication against AIDS. They conclude that while policy makers in the two 
countries have used different approaches to tackle the AIDS problem, they have been able, 
with the support of NGOs, to modify TRIPS and change some WTO rules at the global 
level along legal interfaces. At the national level the results of the fight against AIDS have 
been encouraging for Brazil, but not for South Africa, where authorities denied the chal-
lenge for a prolonged period of time. The authors see the different outcomes as a conse-
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AIDS, Zugang zu Medikamenten und die unterschiedliche Rolle der brasilianischen 
und südafrikanischen Regierungen im Rahmen von Global Health Governance 
Dieser Aufsatz zeigt, wie die Hauptakteure von global health governance – Regierungen, 
Nichtregierungsorganisationen (NGOs), intergouvernementale Organisationen (IOs) und 
die transnationalen pharmazeutischen Unternehmen (TNPCs) – durch intensive Interakti-
onen die globalen Regelungen zum Gesundheitswesen im Allgemeinen und zur Behand-
lung von AIDS im Besonderen entscheidend modifiziert haben. Ausgehend vom Begriff 
der verschiedenen Machtformen (Keohane/Martin) und Schnittstellen (interfaces, Norman 
Long), untersuchen die Autoren die Konflikte zwischen den genannten Akteuren, entstan-
den aus dem beschränkten Zugang zu den teuren antiretroviralen HIV/AIDS-Medikamen-
ten – u.a. eine Folge des 1995 in Kraft getretenen Agreement on Trade Related Intellectual Pro-
perty Rights (TRIPs). Sie gehen sodann auf die unterschiedlichen Politiken der AIDS-
Bekämpfung in Brasilien und Südafrika ein und kommen zu dem Schluss, dass diese Län-
der es zwar gemeinsam mit anderen Ländern und den NGOs geschafft haben, einige 
WTO-Regeln auf globaler Ebene zu verändern, dass die Ergebnisse auf nationaler Ebene 
jedoch auseinanderklaffen – enttäuschend für Südafrika, wo das Problem lange Zeit igno-
riert wurde, und ermutigend für Brasilien, dank einer gelungenen Kombination der dis-
kursiven, legalen, organisatorischen und ressourcenbezogenen interfaces. 
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During the 1990s the number of people dying of HIV/AIDS in developing countries was rap-
idly increasing; effective medicines to turn the pandemic into a chronic, but not necessarily 
deadly, disease were increasingly available, yet they were not affordable for the vast major-
ity of affected people in developing countries. Transnational pharmaceutical companies 
(TNPCs) were in a position to charge high prices for innovative medicines, particularly in 
the case of AIDS antiretrovirals (ARVs). They were supported by the Agreement on Trade 
Related Intellectual Property Rights (TRIPS), introduced with the establishment of the 
World Trade Organization (WTO) in 1995, which demands the harmonization of intellectual 
property rights (IPRs) in all member countries. 
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The conflicts between a group of industrialized countries in the “North” and a growing 
group of emerging economies in the “South” centered around access to ARVs in particular 
and, eventually, access to medicines for the poor in general. These conflicts provide fascinat-
ing insights into the changing pattern of global health governance because they have as-
sumed a multidimensional character and involve—in addition to groups of countries de-
fending and opposing strict IPRs—a large number of civil society organizations (CSOs) net-
worked by the Médecins sans Frontières (MSF) access campaign.1 When the South suc-
ceeded in having the prices of ARVs significantly lowered as a result of negotiations with 
the TNPCs, the developing countries were also able to reach international agreements to 
clarify the right to use TRIPS safeguards. These included compulsory licenses2 and parallel 
importation used to “protect public health” and, thus, decrease the risk of trade conflicts re-
lated to the stringent patent-right protection. 
The course of these conflicts points to the changing character of international relations over the 
last 20 years. Relations between state actors have been increasingly challenged through a densi-
fication of global social relations where private actors (CSOs as well as corporations) have a 
growing impact on the course of events. States remain important as they conclude binding in-
ternational agreements, provide the hardware of public health care (Fidler 2007), and thus con-
tinue to play a crucial role in pursuing strategies to deal with health issues. Therefore, ap-
proaching the issue of access to ARV by analyzing the interaction of public and private actors 
in global politics as well as in two important developing countries will help us move towards a 
better understanding of how health problems are tackled in a globalizing society. 
We understand global health governance (GHG) as “the totality of collective regulations to 
deal with international and transnational interdependence problems in health” 
(Bartsch/Kohlmorgen 2005: 64). These regulations are, simultaneously, the results of conflic-
tive and cooperative processes and the starting points of new conflicts about specific health 
policies (such as providing universal access to ARVs). These processes imply “interfaces” 
between actors with conflicting perceptions, values, and interests due to the systemic con-
texts in which they operate. This essay will focus on the changing nature of those interfaces 
and the change in power relationships, which came as a big surprise to both the actors and 
the observers. 
The first part of the essay will start with some theoretical observations concerning the four 
different kinds of interfaces and their impact on the outcome of global negotiations. This 
will be followed by an analysis of the IPR-related conflicts linked to the TRIPS Agreement 
and access to medicines, which basically involve the interests of TNPCs and their impact on 
government policies in the North. The second part of the paper, focusing on Brazil and 
                                                     
1  The role of global civil society in this conflict is analyzed in more detail in the chapter by Burris et al. in this 
volume; see also: Sell/Prakash 2004; Hein et al. (2007). 
2  Under WTO rules, a compulsory license allows governments to produce or to grant a third-party authority to 
produce a drug without consent of the patent holder in cases of national public health emergency, among 
other limited circumstances (www.wto.org/English/thewto_e/minist_e/min01_e/mindecl_trips_e.htm). 
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South Africa, will examine the different types of interfaces which have driven these conflicts 
and compromises between national health governance (NHG) and GHG in the context of the 
global fight against HIV/AIDS. A closer look at the health policies of these two countries in 
general and their fight against AIDS in particular will make it possible to examine both the 
power relationships between the North and the South and the nature of the interfaces in 
some detail. 
We will maintain that the NHG of the two regional powers Brazil and South Africa has 
played a crucial role in determining how global challenges are taken up and how the 
chances to influence GHG are realized. Their sociopolitical settings have allowed both coun-
tries to pursue different objectives in fighting HIV/AIDS and interacting with the global 
level. In the process, the two countries have changed the very economic and social structure 
of both their own NHG and GHG. 
2 Changing Power Relationships and the Role of Interfacing: A Few Theoretical 
Considerations 
 “Interfaces” are (following Long 1989) defined as “socio-political spaces of recurrent inter-
actions of collective actors in the handling of transnational and international affairs” 
(Bartsch et al. 2007: 30). An analytical differentiation is made between four major types of in-
terfaces which are closely related to the different types of power employed, that is, legal, re-
source-based, organizational, and discoursive (ibid.). This differentiation helps to highlight 
the change in the relative importance of different means of interaction in shaping the finan-
cial and economic—as well as the institutional, political, and social—aspects of national and 
global health governance 
Actors in global governance have traditionally dealt in two modes of governance, either in-
volving intergovernmental interaction or, in the private sphere, business negotiations. In re-
cent decades, however, cooperation between actors of different types (public-private part-
nerships, PPPs) has become more and more frequent, constituting hybrid forms of regula-
tion. Moreover, the actors and their actions have been shaped by structural economic, politi-
cal, and sociocultural conditions. This implies that actors—by virtue of their structural posi-
tion and role—have certain features, tasks, and resources that affect their capability to exe-
cute power. As global governance is primarily regarded as the sum of interactions between 
actors, it becomes necessary for the empirical study to follow a corresponding approach 
which is focused on public-private interactions. While the world markets, with their dispari-
ties and the potency of certain actors, should be regarded as the framework of the actors’ in-
teractions and as the origin of their power, they have only been considered that in a few re-
search efforts (Barnett/Duvall 2005b; Arts 2003). A study that is focused on power should fa-
cilitate a sophisticated analysis that allows for the identification of not only the apparent 
power of the resource-rich actor but also the potency of “weaker” actors. Based on Bar-
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nett/Duvall (2005) and on Bas Arts (2003), who examine the power of non-state actors in 
global governance, we differentiate between four types of power: 
• Decision-making power (refers to the actors’ ability to be involved in decision making 
and in formal norm setting) 
• Legal power (the ability to exert power based on legal structures and laws) 
• Resource-based power (refers to the actors´ material resources (for example, money, 
funding) and immaterial resources (knowledge, information) and their ability to provide 
these resources) 
• Discoursive power (the ability to frame and influence discourses) 
We will see that these different types of power are closely related to specific types of inter-
faces between various actors and levels of global governance. There is, however, also a lack 
of detailed scientific investigation on the meaning of interests in the realm of the global gov-
ernance. Most authors presume the existence of collective interests. However, this obscures 
the fact that the actors’ self-interests are highly significant in questions regarding which 
governance structures have to be used and in which manner, how these structures could be 
modified and redesigned, the extent to which the process of interaction takes a cooperative 
or conflictive course, and which policy outcomes are feasible under these circumstances. 
Followers of the rational institutionalism school (Keohane/Martin 1999) rightly point out 
that institutions are more than just short-term entities which emerge because of rapid com-
binations of power and interests but that at the same time their momentum should not be 
overestimated. They argue that actors and their interest-oriented and instrumental-rational 
actions are an essential factor in expounding the emergence and function of international in-
stitutions. This creates different combinations of common, complementary, or conflictive in-
terests depending upon the position of actors in global and national societies; we will refer 
below to the differentiation between market-creation interests and welfare-oriented inter-
ests, which is of particular importance in global governance processes. 
The extent to which individual interests or overarching goals of social welfare determine the 
actors’ behavior is, last but not least, dependent on their logic of action. March/Olsen (1989) 
have outlined an orientation that is prevalent in rationalist approaches to actor behavior and 
called it the “logic of consequentialism.” This is characterized by individual utility maximi-
zation, strategic action, the rational pursuit of interests, and consistent goal-oriented behav-
ior; it basically relates to a “realistic” pursuance of self-interest which might be based on an 
actor’s position in the economic system and possibly also on the fight for political power. 
Social integration, however, depends on more than just complying with rules because of the 
self-interested desire to avoid punishment. March and Olson confront the logic of conse-
quentialism with a ”logic of appropriateness“ which assumes that actors behave according 
to overarching norms and do what they believe is considered appropriate in the eyes of 
other actors. Risse (2000) supplements these “logics” with the “logic of arguing,” implying 
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that actors exchange arguments on causal and normative contexts through a communicative 
process and act according to the results of such a process of understanding. This implies that 
even in the realm of rational action—discarding the emotional/affective binding forces of a 
community—society depends upon a logic of collective understanding which works inde-
pendently from a continuous reference to long-term self-interest. 
Seen in relation to processes of global governance, these considerations mean that we have 
to take into account a certain combination of actors primarily following a logic of conse-
quentialism and other actors following the logics of appropriateness and/or arguing. It 
would be a mistake to relate actors in the economic field and in the social field simply to the 
first and the second logic, and also to assume that one actor is always following the same 
type of logic (for example, corporate social responsibility). The formation of a global society 
implies not only states pursuing their national interests and transnational actors pursuing 
their collective interest to create global rules—which allow them to pursue their private in-
terests globally (critical interpretations of WTO)—but also the strengthening of advocative 
actors pushing human rights and supporting “health for all” politics in order to create the 
necessary confidence for global cooperation. 
Analyzing interfaces thus implies describing and examining the actors involved in global 
governance interactions in their original structural contexts, that is, their sets “of reference 
points and constraining/enabling properties” (Long 2001: 62). Interfaces represent the inter-
sections of modes of life, worldviews, interests, and strategies in which power relations are 
important for the emergence of new institutional contexts. As we are particularly interested 
in the impact different actors have on shaping institutional change and policy outcomes in 
GHG, we propose a typology of interfaces in relation to the types of power, namely, deci-
sion-making, legal, resource-based and discoursive power. There is a certain congruence be-
tween types of power and specific types of interfaces. 
Certainly, it makes sense to talk of discoursive interfaces when considering not only the role of 
mass media but also the importance of expert commissions that produce reports intended to 
shape the perspectives of influential persons on important political issues (thus constituting 
the use of discoursive power). In addition, there are resource-transfer interfaces involving the 
relationships between donors (countries, foundations) and international governmental or-
ganizations on the one hand, and the latter type of organization and receiving countries or 
other actors on the other hand. With respect to decision-making power, it seems useful to 
distinguish organizational interfaces, that is, decision-making structures in relevant organiza-
tions and institutions. Legal interfaces are created not only by international law (and are a 
specific outcome of processes at organizational interfaces)— which is exercised by interna-
tional bodies monitoring compliance with this law (such as the WTO Dispute Settlement 
Body)—but also by national courts when dealing with international law incorporated into 
national law (for example, patent law following TRIPS rules). We define discoursive, organ-
izational, legal, and resource-transfer interfaces as follows: 
10 Wogart/Calcagnotto/Hein/von Soest: AIDS—Brazil’s and South Africa’s Roles in Global Health Governance 
• Discoursive interfaces are communications about a basic understanding of, but also on, 
strategies to deal with the issues that arise in interactions between different levels of 
politics and different types of actors. These strategies might involve programmatic ele-
ments if longer-ranging concepts of cooperation and problem-solving are developed. 
• If these programs are related to existing or newly created organizations, organizational in-
terfaces appear, which in the case of international/global organizations typically comprise 
actors from the international and national levels of politics (partnerships, participation in 
organization and/or decision-making bodies, operational cooperation, consolidated pro-
grammatic cooperation). 
• Organizational interfaces, depending on the nature of the organization, might also in-
clude legal interfaces, which are structured through international and national law (actors 
attempting to influence legislative processes and negotiations, the implementation of 
law, legal conflicts, and international agreements). 
• Resource-transfer interfaces play a particularly important role in the transfer of finances to 
poor countries, and, of course, in financial transfers from rich countries to multilateral 
organizations in various fields of social politics. Resource-based interfaces also arise as a 
strategy to defend specific regulations (or the prevalence of specific political regimes) 
against irrefutable criticism, for instance, from a human rights perspective. The transfer 
of resources occurs not only between different levels of politics (typically, national > in-
ternational > national) but also between different policy areas and types of actors (for ex-
ample, nation states > CSOs; or IGOs (intergovernmental organizations) > CSOs). Re-
source-transfer interfaces can relate to both material resources (for example, funding) 
and immaterial resources (for example, labor force, technical assistance, knowledge). (s. 
for more details: Hein/Bartsch/Kohlmorgen 2007: 30 ff.) 
The “recurrent interactions” between major GHG actors discussed in this essay have mani-
fested themselves in different ways according to the types of interfaces involved. It is as-
serted here that while closely interconnected, discoursive interfaces and their worldwide re-
percussions have been more important in shaping the conflicts around access to treatment 
for HIV/AIDS patients than the seemingly powerful resource-based interfaces, and that the 
emerging legal and organizational interfaces reflect the power of discourses in GHG. Both 
assertions—if proven correct—should have significant policy implications for present and 
future global governance in the health sector and beyond. 
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3 Internationalizing Intellectual Property Rights 
The process of globalization has been accompanied by an increased need to base the integra-
tion of global markets on international law. The interest of the technologically leading indus-
trialized countries in strengthening international rules on IPRs has to be seen in the context 
of protecting those IPRs created by advances in computer and information technology, bio-
technology, and the patentability of life organisms. Besides a further deepening of GATT in 
the WTO context, including a strengthening of dispute settlement mechanisms, the North 
has introduced other agreements which have affected GHG directly and indirectly. They in-
clude the General Agreement on Trade in Services (GATS) and the Agreement on Sanitary 
and Phytosanitary Measures (SPS). While GATS constitutes an extension of trade liberaliza-
tion for trade in services with far-reaching implications for the national regulation of ser-
vices—the majority of which was formerly operated by nation states only—TRIPS and SPS 
are totally new types of agreements in the GATT context, although the internationalizing 
and institutionalizing of IPRs is a venerable tradition dating back to the nineteenth century.3 
With the establishment of the World Intellectual Property Organization (WIPO) in 1967, in-
ternational protection of IPRs reached a new level of institutionalization. Even then, many of 
the fully developed countries were not members, and it took another 20 to 30 years before 
such major industrialized countries as Canada, Austria, Spain, Switzerland, and Norway 
adopted strong patent protection which reflected the rules and regulations elaborated by 
WIPO in an international setting. However, WIPO’s one country-one vote rule led to stale-
mates. Furthermore, WIPO did not have any strong mechanism to enforce compliance. 
Therefore, the US and other developed countries with strong interests in protecting IPRs 
looked at the enforcement and dispute settlement system which existed within GATT and 
which was to be further developed in the context of the WTO agreements. Within the con-
text of that institutional setting it was possible to put pressure on advanced developing 
countries, which were known not only to copy and reengineer innovations, but also to have 
been successful in exporting those more sophisticated products all over the world. In the 
pharmaceutical field the increasing competition of international generic producers, which 
circumvented the strict patent laws of the US and other OECD countries, was increasingly 
perceived as hurting sales of patented drugs, both at home and abroad. 
Moving the focus of implementing international IPR rules from WIPO to TRIPS represented 
the first round of “forum shifting” in this field, which means an attempt to shift the main 
thrust of an actor (or a group of actors) fighting for an international agreement serving its 
(their) objectives to a different international organization or forum (cf. Drahos 2002, 
                                                     
3  After the Paris Convention for the Protection of Industrial Property (1883), and the Berne Convention for the 
Protection of Literary and Artistic Works (1887), a common international secretariat was established in 1893. 
During the first half of the twentieth century, the political and economic upheavals of the two World Wars 
and the economic problems associated with them did not allow any further institutionalization until 1967, 
when the Stockholm Convention Establishing the World Intellectual Property Organization (WIPO) was 
signed. 
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Sell/Prakash 2004). The same strategy was also used by the pharmaceutical companies and 
the US negotiators in bilateral trade agreements. The early ones, such as the North American 
Free Trade Agreement (NAFTA), were negotiated either before or at the same time as the 
TRIPS Agreement. Most of the other ones were signed in the late 1990s and the move to-
wards bilateral agreements has continued during the first five years of the twenty-first cen-
tury. All of them contained more rigid IPR stipulations, in particular the exclusion of TRIPS 
flexibilities for pharmaceuticals also. These so-called “TRIPS+” agreements became the rally-
ing points of opposition to the trade agreements in the respective countries. Even respected 
free-trade advocates such as Jagdish Bhagwati described the WTO’s intellectual property 
protection as a tax that most poor countries paid on their use of knowledge, “constituting an 
unrequited transfer to the rich producing countries“ (Sexton 2001: 10). 
In the second half of the 1990s, however, CSOs won growing public support to press TNPCs 
and developed countries to help improve access to essential medicines, in particular ARVs, 
using discoursive interfaces. Public support also proved decisive in preventing TNPCs full 
use of their presumably strong legal and resource-based position. In 1997 (and again in 2001) 
the Pharmaceutical Manufacturer’s Association of South Africa went to court to fight against 
a law that allows domestic production of generics, but in both cases decided to withdraw 
due to the pressure of global public opinion and CSO action. Negotiations with Brazil on 
ARVs (delivery and licenses) lead to steep price reductions in 2001, despite calls for the 
United States Trade Representative (USTR) to threaten legal action at the WTO (discussed in 
more detail in the latter part of this section). As a consequence of these conflicts, CSOs and 
developing countries, led by Brazil, took the initiative to press for a clarification of the right 
to use TRIPS flexibilities in the pursuit of public health. This led to the Doha Ministerial Dec-
laration on the TRIPS Agreement and Public Health in November of 2001. 
The Doha Declaration defined the relationship between the protection of patents and its 
limitation in the context of public health emergencies, making clear that WTO members’ 
right to protect the health of their populations should make it possible to access medication 
at the lowest possible prices. That unanimous decision was finally reached because of the 
rapid spread of AIDS in developing countries. It took another two years, however, before a 
final agreement, stipulated by the famous paragraph 6 of the Doha Declaration, was 
achieved. This agreement created a system to allow countries which were not able to pro-
duce low-cost generic medicines themselves to issue compulsory licenses to have them pro-
duced in a foreign country.4 
                                                     
4  The 2003 Decision actually took the form of a waiver related to the obligations of the Member countries under 
Articles 31f and 31h of TRIPS. To soothe the fear of TNPCs and their governments in the developed countries, 
the General Council’s Chairperson underlined the fact that the “system that will be established by the Deci-
sion should be used in good faith to protect public health and, without prejudice to paragraph 6 of the Deci-
sion, not be an instrument to pursue industrial or commercial policy objectives” (WTO News, 2003). For a de-
tailed legal interpretation and a discussion on the relationship between the Decision and the Amendment see, 
South Centre and CIEL, 2006. 
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WTO members finally approved these changes to Article 31 of the TRIPS Agreement in De-
cember of 2005.5 After ten years of the WTO’s existence, this was the first time a core agree-
ment of the organization had been amended. To what extent the Doha Declaration and the 
TRIPS amendment will facilitate compulsory licensing to improve access to medicines re-
mains to be seen. As of 2008, only a few countries of the South, such as Thailand and Brazil, 
have used compulsory licensing, and only Rwanda has used the new mechanism introduced 
in Art. 31. Officials of smaller and poorer countries have generally not issued compulsory li-
censes, either because there were too many cumbersome regulations or because the research-
oriented TNPCs were willing to provide low-cost versions of their patented products.6 
In the meantime, the deadline for the least developed countries to enact and implement pat-
ent and other IPRs has been postponed to 2016. The TRIPS Council took that decision during 
the Hong Kong Meeting in 2005, following the LDCs earlier request for the extension. The 
developing countries’ increasing involvement in the international negotiating process on 
matters touching on health governance has been a constant feature of negotiations on the 
“amended” TRIPS Agreement. While we will discuss the latter process referring to the ex-
ample of legal and organizational interfaces in Brazil and South Africa, it can already be 
stated that the very process of getting the TRIPS Agreement amended represented a para-
digm shift in international negotiations, not only because the “voices of the poor” were 
heard but also because their requests were legislated. 
4 The TNPCs, TRIPS, and AIDS 
4.1 Summary Sequence of the TNPCs’ Interfaces 
The interactions between TNPCs and the other major actors in the global and national health 
arena have been analyzed in more detail in earlier contributions; Table 1 summarizes only 
the timeline of events related to IPRs and access to essential medicines.7 These events took 
place between 1994 and 2006.8 What was unique in this case was that not only were the 
TNPCs the major actors in the fight with the government officials of the South over prices of 
the ARVs against AIDS, but they were also responsible for the introduction and negotiation 
of TRIPS and TRIPS+ in the US bilateral treaties, even though those were officially govern-
mental interactions. Their involvement was based on the fact that they have vast financial 
                                                     
5  As in 2003, the compromise in 2005 was reached as a hopeful overture to the WTO trade negotiations, which 
followed suit. 
6  Companies such as GlaxoSmithKline (GSK) and Merck used different packaging and/or bottling and emboss-
ing of their tablets for their HIV/AIDS medication than for the same pills sold in rich countries. They also 
provided a different number of pills per package. 
7  For the conflict between Brazil and the TNPCs see Wogart/Calcagnotto (2006). For the discussion on TRIPS 
see Wogart (2007) and Hein (2007). 
8  See Chapters 2, 3, 7 and 8 in Hein et al. (2007). 
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resource-based power and that they have also become increasingly involved in the decision 
making and formal norm-setting of GHG—that is, in using legal interfaces.9 
Table 1: Timeline of Decisions and Conflicts around IPRs and Access to Medicines 
Year Agreement 
1967 WIPO 
1994 TRIPS /Uruguay Round 
1996 CSO access campaign started 
Beginning of free-of-charge ARV distribution in Brazil 
1996–
2001 
Brazilian negotiations with TNPCs for lower ARV prices and favorable licenses for local production 
1997 1s South African court case; TNPCs withdraw under pressure from CSOs 
2000– Growing number of bilateral trade agreements with strong IPR provisions (without TRIPS flexibilities, 
TRIPS+) 
2000 TNPCs improve access to ARVs through PPPs and differential pricing 
2001 Initiative of South/CSOs: Doha Declaration 
2003–05 Paragraph 6 negotiations/ TRIPS amendment/ deadline for TRIPS implementation in LDCs postponed 
to 2016 (concerning pharmaceuticals). 
2006 South introduces Global Framework on Essential Health Research within WHO 
2007 Establishment of Intergovernmental Working Group on Public Health, Innovation and Intellectual 
Property in WHO 
Source: Authors’ compilation. 
As a consequence of that involvement, the TNPCs found themselves in a number of interfaces, 
ranging from legal ones—encounters with the South African government in the country’s 
courts and the drafting and discussion of the TRIPS legislation with the USTR—to organiza-
tional and discoursive interfaces. The latter types of interfaces played an important role in the 
fight over drug pricing with Brazil’s government and NGOs as well as in key discussions with 
public and private partners and opponents. In both cases TNPCs were involved through their 
major associations at the national and international level (PhRMA and IFPMA) and via the top 
executives of the major companies. They also used resource-based interfaces, utilizing their 
vast financial resources on all fronts. Most of the encounters were really a combination of at 
least two or three types of interfaces. By putting too much emphasis on the legal interfaces at 
the beginning of the discourse on access to medicine in poor countries, they did not achieve 
the expected results, as they admitted quite openly afterwards.10 
                                                     
9  For a discussion of the direct involvement of the TNCs in national and global politics, see Sell (2000) and 
Jawara/Kwa (2003). 
10  The Economist (2005b). 
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4.2 TNPCs’ Strategies and the Response from Brazil and South Africa 
Analysts within the pharmaceutical industry have long used game theory when providing 
strategic advice to management. In deciding among alternative research projects, which not 
only face a significant risk of failure but also the possibility of strong competition, even after 
many years of successful R&D, management is well advised to use this approach to help 
choose which projects to sponsor and which to drop or delay.11 In the case of internationaliz-
ing IPRs, the TNPCs chose the regime-shifting strategy, which they considered to be secure 
since it had the backing of the US government. That strategy did seem to work well at the 
beginning, when the shift of a new legal and enforceable base for IPRs from WIPO to the 
WTO was accomplished without major opposition. 
By simultaneously pressing for the internationalization of IPRs at WIPO (into which the US 
government introduced the Sustained Patent Treaty (SPT)), attaining the successful intro-
duction and legislation of the TRIPS Agreement at the WTO, and insisting on even tougher 
IPR regulations (TRIPS+) in various bilateral treaties, the governments of the North in gen-
eral and the US Trade Representative in particular followed the script designed by the high-
tech Transnational Corporations (TNCs), among which the TNPCs played a crucial role.12 
The TNPCs’ success on the national front encouraged Brazil and the NGOs to also play an 
increasingly more active and demanding role in the international global health arena along 
legal interfaces, and to mobilize discoursive ones. The outcomes of these activities were two 
initiatives within WIPO and WHO. In 2004, under the leadership of Argentina, Brazil, and 
Kenya, the developing countries pushed for negotiations on a “development agenda” within 
WIPO and a medical R&D treaty within WHO; these initiatives were intended to provoke 
further discussion on the value of and the best timing of IPRs legislation in developing 
countries (see Figure 1). 
By also using the strategy of forum shifting, the South countered the initiatives of the North 
with an increasing number of initiatives which transferred the limelight of global health is-
sues from the WTO to the WHO, where it would seem to belong. The scenario depicted in 
Figure 1 illustrates the multiple interfaces among the major actors in the health arena of to-
day. From earlier discussions regarding the TNPCs’ interactions with and influences on the 
governments of the North, in lobbying for the internationalization of IPRs in various fora, 
and the response from the developing countries, fighting for an amendment to TRIPS and in-
troducing new initiatives at WIPO and the WHO, it has become clear that the major pillars of 
the global health architecture are in the process of significant change. They will continue 
change in the near future. While neither the TNPCs nor the NGOs belong to those “pillars,” 
their actions and interactions have played a major role in bringing about the transformation 
of such venerable institutions as the WHO, the World Bank, the WIPO, and the WTO, the lat-
                                                     
11  See for example Senn 1996; ‘Game Theory and Business Decisions’, http://faculty.haas.berkeley. 
edu/xuanming/147/. 
12  For an extensive discussion of the TNPCs’ role in drafting the TRIPS Agreement, see Sell (2000). 
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ter two of which would previously never have been anticipated to become part of wide-
ranging discussions and decisions concerning global health issues in the twenty-first century. 





















Notes:                      = legal interfaces 
                     = discoursive interfaces 
                     = organizational and resource-based interfaces 
Source: Authors’ compilation. 
Brazil and South Africa have faced major HIV/AIDS crises, with “important aspects of the 
epidemic following a similar pattern in both countries” (Gauri and Lieberman, 2004: 2). 
While experts predicted a major expansion of the disease in both countries in the mid-1980s, 
Brazil has been able to keep the prevalence rate at less than 1 percent of its population 
(UNAIDS, 2004: 202). The 660,000 estimated HIV cases in Brazil contrast with 5.54 million 
HIV-infected South Africans, who constitute close to 11 percent of the country’s population 
(Doherty and Colvin 2004: 196). Table 2 summarizes the major similarities and differences 
between the two countries concerning their readiness to fight HIV/AIDS. 
With national incomes at similar levels and public health expenditures constituting a similar 
share of public expenditures, the governments of the two countries were equipped with a 
similar resource base to fight the disease, notwithstanding Brazil’s greater external foreign 
debt exposure. In short, based on economic and social positioning, South Africa would have 
seemed to be at least in a similar if not better position to fight the HIV/AIDS pandemic than 
Brazil; yet the opposite occurred. While the Brazilian government rolled out the ARVs free 
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of charge in 1996 (AZT as early as 1991), the South African government only started doing 
this in 2003, and even then reluctantly. The startling difference in behavior can also be ob-
served in the relationship those two countries’ actors had with GHG representatives. 
Table 2: Brazil’s and South Africa’s Fight against HIV/AIDS: Similarities and 
Differences 
Item Brazil South Africa 
HIV-infected people 1992: about 
770,000 or prevalence-rate < 1% 
 




Actual HIV prevalence 2006: 
0.61%; i.e., 620,000 HIV-infected 
people 
HIV prevalence 2006: 11% (5.54 million HIV-
infected people) 
Per capita income US$3000 (2006) US$3630 (2004) 
Income distribution Seriously unequal (Gini-Index: 
59.3—2005) 
Seriously unequal (Gini-Index: 57.8—2005) 
Public health expenditures 7.3% of federal budget with ad-
ditional state and municipal 
spending 
11.5% of total public budget 
ARV distribution free of charge 
(year of implementation) 
Since 1988, DST-medication; 
since 1991, AZT; since 1996, ARV 
distribution 
Since April 2002, legal entitlement for HIV-
positive mothers (Nevirapine); since Novem-
ber 2003 for all citizens 
HIV/AIDS treatment policy at 
federal level (year of implementa-
tion) 
Since 1985: National HIV/ AIDS 
Program 
1994: National AIDS Plan 
Note: Gray-colored cells indicate major divergences between Brazil and South Africa. 
5 Mutually Reinforcing Interfaces in Confronting the AIDS Challenge 
5.1 Resource-based and Discoursive Interfaces: Provoking Different Responses in 
Brazil and South Africa 
The Brazilian response to AIDS emerged from the demands of civil society groups and de-
veloped through active collaboration between the local government of São Paulo and NGOs 
and through support from within the official health system, first at the state level, then—
after a delay of three years—at the federal level. The civil society organizations had been the 
most critical opponents of federal government health policies in the 1980s and early 1990s 
because of governmental reluctance to formulate a comprehensive national HIV/AIDS pro-
gram. During the first years of the epidemic NGOs remained, together with some local gov-
ernments, the protagonists of prevention and care (Galvão 1994: 341-352).13 In these efforts 
                                                     
13  This changed with the new orientation of the Brazilian Sexually Transmitted Diseases and HIV/AIDS Pro-
gram (BHAP) in 1992, providing a wide range of prevention and care services. The development of a network 
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they also drew heavily on resources from abroad by interfacing with global actors through 
the Internet and at international AIDS conferences. 
Since the Brazilian public health system had been suffering from continued lack of finance 
(aggravated by the debt crisis), the gap between the rapidly growing need for AIDS treat-
ment and the scarce financial resources became ever greater in the late 1980s and early 
1990s. A 1989 estimate revealed direct treatment costs for each AIDS patient to be approxi-
mately US$15,670/year, with total costs of US$3.5 billion for all known AIDS patients. One of 
the arguments for government provision of free treatment was that the treatment was ex-
pected to have both a care and a prevention effect.14 
The prevention versus treatment question became a controversial issue in discussions be-
tween the Brazilian government and the World Bank during loan negotiations as of 1992. 
With the reorganization of the National AIDS Program in the Ministry of Health, there was a 
concerted effort on all sides (governmental programs at every level, NGOs, universities) to 
work together in seeking to build a national response to the epidemic. This collaborative 
spirit was reinforced and solidified during the process of elaborating a proposal for the first 
World Bank AIDS Project (1994–98), in which traditional rivalries and territorial disputes 
were set aside in favor of cooperation in fighting the disease.15 While the bank did not fi-
nance treatment directly, the national component of the funds did and the funds going from 
the bank to the NGOs did too, in one way or another. Together with the AIDS II project 
(1998–2003) and the following AIDS III project, the bank provided US$435 million, which 
was supplemented by a government contribution of US$325 million. There was a special 
emphasis on prevention services, epidemiological surveillance, capacity building, and the 
improvement of the quality of life of people living with HIV/AIDS. 
The World Bank projects were a watershed—quantitatively and qualitatively—since they 
induced a high degree of commitment on the part of the government and included decisive 
financing of NGOs. There was a dramatic expansion of federal government program expen-
ditures for HIV/AIDS/STD16 treatment, in addition to ARV and other drugs, after the bank 
had begun to disburse. The World Bank helped not only through financing capacity build-
ing and creating facilities at the state and municipal levels, but also through financing pre-
vention projects run by CSOs, thus consolidating one component of the overall Brazilian 
                                                                                                                                                                     
of NGOs has since then mainly been financed by the federal government, which has channeled funds from 
World Bank projects to them. 
14  “The promise of treatment gave an incentive for more at-risk individuals to be tested and gave doctors an in-
centive to report AIDS cases, thus improving surveillance and prevention programs” (Berkman et al. 2005: 
1170). For instance, the implementation of BHAP in 2001 required an investment of US$232 million, but was 
estimated to result in total savings of US$1.1 billion (thanks to the reduction of hospitalization and other 
costs). 
15  The minister of health, José Serra (1998–2002), maintained somewhat dryly in an interview: “The bank’s par-
ticipation was positive for it obliged us to do something well organized to make an efficient management and 
accounting effort“ (see J. Biehl, 2004). 
16  STDs: sexually transmitted diseases. 
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STD and HIV/AIDS program BHAP.17 Fostered by the joint AIDS I-III projects of the BHAP 
and the World Bank, the number of CSOs addressing HIV/AIDS grew rapidly from 120 in 
1992 to more than 500 in 1998 (Bacon et al. 2004: 45) and 1884 in 2003 (Monitoraids 2004). 
The increased interfaces between HIV/AIDS CSOs and BHAP seem to have contributed to a 
better overall relationship between civil society and the state in Brazil. 
The fact that the bank agreed to have the operations used for both prevention and treatment 
would not have been possible without the intense use of discoursive interfaces in the form of 
strong and skilful argumentation related to the country’s newly awakening democratic spirit 
and the willingness for coordination articulated by the national government and critical 
NGOs such as ABIA18 and others. These civil society organizations helped to restrict the 
World Bank’s influence to an almost exclusively resource-transfer character; consequently, 
the Brazilian government could maintain its comprehensive prevention-treatment approach 
(cf. Calcagnotto 2007: 193 and Parker et al. 2001: 110). In short, Brazil has jointly used re-
source-based and discoursive interfaces, both within the country and internationally. 
Other external donors have supported HIV/AIDS programs in Brazil, but their financial con-
tributions have been relatively small. Among others, there has been bilateral support from 
the major aid agencies of the OECD countries: USAID, CDC, DPID, GTZ, and ANRS. The 
discoursive interfacing has in some cases reached crisis proportions. For instance, in 2005 and 
2006 it led to the refusal of an offered USAID credit of US$40 million because of the USAID 
insistence on the ABC approach (“Abstinence, Be faithful, and Condoms”, in this order of priority), 
which is rejected by Brazilian authorities especially in relation to sexual workers and absti-
nence. But despite dissent along discoursive interfaces, the cooperation related to resource-
based interfaces between BHAP and USAID goes on in other SDT/HIV related activities.19 
Particularly in the foundation period (1985–1992), CSOs working on HIV/AIDS relied heav-
ily on sources from abroad, such as the Ford Foundation, Misereor, Brot für die Welt, and 
they worked actively along discoursive interfaces with international CSOs. 
The financial and discoursive interfaces have also been intense between the Brazilian busi-
ness sector, government, and civil society. As part of the BHAP the Brazilian National AIDS 
Council (CEN) has not only been active in supporting workplace programs within its mem-
bership, but it has also played an important global diffusion function in disseminating the 
best practices of those programs on the shop floor. It was in that context that multinational 
                                                     
17  The relevance of this qualitative contribution is reflected in the prevention component, for which the bank 
lent US$253m in the period 1994–2003. The federal government alone spent a total of US$290m in 2000 for 
ARV drugs purchasing, which was 69 percent of total federal spending on AIDS in 2000 (Beyrer et al. 2005: 
28). It would have been difficult for the Brazilian government to spend so much for treatment over all the 
years if the World Bank had not covered the prevention component so massively. 
18  The Brazilian Interdisciplinary AIDS Association, founded in 1986. 
19  S. “Nota Técnica do Programa Nacional de DST e AIDS” in: www.aids.gov.br/main.asp?View={E77B47C8-
3436-41E0-AC19-E1B215447EB9} of 13.03.2006 and www.reduc.org.br/news.php?recid=125, accessed 8.1.2008; 
also: http://brazil.usaid.gov/noticiaINT.php?id=90, from 10.12.2007. 
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business and private foundations began to view NGOs and labor unions as partners fighting 
HIV/AIDS (cf. Terto 1997: 154). 
South Africa’s encounter with the HIV/AIDS challenge was—on the governmental level—
influenced neither by financial contributions nor by discoursive interfaces with global actors 
for a considerable time period. According to Schneider and Gilson (1999: 266), total interna-
tional aid to the health sector was just over 1 percent of the South African annual govern-
ment health budget in the period 1994–1999. As a middle-income country with relatively 
low external debt,20 South Africa was not willing to rely on conditional donor aid. Through-
out the 1990s the ANC government thus refused external offers of financial or technical as-
sistance, which it did not see as fitting into its policy framework, particularly with respect to 
treating HIV/AIDS. 
This contested approach came into the open in 2002, when the ANC government blocked 
the disbursement of US$72 million granted by the Global Fund to Fight AIDS, Tuberculosis 
and Malaria (GFATM) to the Enhancing Care Initiative (ECI) of the province KwaZulu-
Natal. Its HIV/AIDS program included—among other activities—the financing of schemes 
to reduce the risk of mother-to-child-transmission (MTCT) of the virus and to provide anti-
retroviral treatment to infected persons (Pawinski/Lalloo 2002). Despite the fact that the 
South African National AIDS Council (SANAC) was not functioning at that time, the minis-
ter of health argued that only the national government could apply to the Global Fund 
(Weinel 2005: 45). It took another two years before the funds were transferred to KwaZulu-
Natal’s ECI. 
Other official inflows of foreign financial support to fight HIV/AIDS were accepted by the 
national government only in 2004, more than a decade after Brazil initiated its large program 
requesting external assistance. The American organization President’s Emergency Fund for 
AIDS Relief (PEPFAR) provided US$221.5 million in 2004/5 for treatment, prevention, care 
of orphans, and palliative care (United States Global AIDS Coordinator 2005: 115). As stated 
by the US embassy in South Africa, 60 percent of the funds were allocated to the South Afri-
can government and 40 percent to civil society organizations working in the field of 
HIV/AIDS (United States 2006). Thus, the ANC government integrated PEPFAR funds into 
its changed strategies to fight HIV/AIDS. 
In contrast to the government’s approach of stressing autonomy, many of South Africa’s 
civil society actors have been partially or fully funded by external actors such as aid agen-
cies, international organizations, or private foundations. Recipients have included the 
Treatment Action Campaign (TAC), the Health System Trust, the AIDS Foundation, and the 
research institute IDASA. The most prominent has been TAC, which—since its foundation 
in December 1998—has quickly emerged as the most vocal civil society actor in the area of 
                                                     
20  In 1996, shortly after the democratic transition, South Africa’s total external debt amounted to US$23.6 billion 
(World Bank 1998: 249), against a total debt of US$83.3 billion for Brazil (only medium- and long-term; Cen-
tral Bank of Brazil 1983: 93). 
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South Africa’s HIV/AIDS policy. Almost the complete organization’s budget of R23.5 million 
for the financial year ending in February 2005 came from foreign donors.21 
Like official resource transfers, discoursive interfaces have been hampered by internal con-
flicts in South Africa and international misunderstandings. Global actors operating in the 
country have only gradually been able to shape discourses on HIV/AIDS in general and on 
antiretroviral treatment in particular. Contradicting government positions, they have been 
able to demonstrate that antiretroviral treatment of HIV/AIDS is an effective and feasible op-
tion for the country. Several examples highlight the difficulty of overcoming South African 
policy makers’ unwillingness to engage in a dialogue on treatment of HIV/AIDS. 
One of the most prominent HIV/AIDS antiretroviral projects emerged in Western Cape 
Province, the only province which, besides KwaZulu-Natal, was not governed by the ANC 
until 2004. In January 1999, MSF started—with the support of the Western Cape provincial 
government—an ARV-based program to reduce the risk of MTCT in Khayelitsha, a large 
township in Cape Town (Médecins Sans Frontières 2003: 14). In May 2001, the organization 
established the first public-sector service to provide antiretroviral treatment to people living 
with HIV/AIDS in South Africa. Although the national government disapproved of this ac-
tion, the political constellation in Western Cape Province permitted the engagement of MSF. 
The Khayelitsha project set a publicly visible example that ARVs could be successfully ad-
ministered, even in a poor township setting. This is reflected in the 2003 report from TAC 
(2003), a close ally of MSF. 
While public-private partnerships developed in Brazil in order to prevent and treat AIDS in 
business and industry, the private sector was on its own in South Africa. Without entering 
into the discussion of whether businesses’ reaction has been adequate to the magnitude of the 
HIV/AIDS problem, it can be safely said that the highly publicized workplace programs of 
such important enterprises as the Anglo-American mining company, the parastatal power 
utility Eskom, and the multinational car manufacturers DaimlerChrysler, BMW, and Volks-
wagen—beyond a having a very specific impact among the firms’ employees and their fami-
lies—set a publicly visible example and thereby influenced South Africa’s HIV/AIDS policy.22 
Civil society was less constrained and interacted significantly with other actors, at both the 
national and the international level. TAC most actively forged networks with international 
nongovernmental organizations (INGOS) and international organizations which had a sig-
nificant impact on GHG. In cooperation with its partners, TAC organized international pro-
tests supporting South Africa’s government in the court case of the Pharmaceutical Manu-
                                                     
21  The main sources were Bread for the World, the Open Society Foundation, the Swedish International Devel-
opment Agency, Oxfam, and the Ford Foundation. Only one donor, the AIDS Foundation of South Africa, is 
based in the country (TAC 2005). The full list of donors along with a detailed analysis can be found in Mbali 
(2005: 22-23). 
22  For case studies on workplace programs in two large South African companies, see Stevens (2004). On work-
place programs in South Africa, see also Marais (2000: 30) and Butler (2005: 11). Further empirical sources 
consist of the interviews conducted during field research in May 2005. 
22 Wogart/Calcagnotto/Hein/von Soest: AIDS—Brazil’s and South Africa’s Roles in Global Health Governance 
facturers Association challenging the Medicines and Related Substances Amendment Act 
(Gumede 2005: 157, see also above). INGOs later also conducted solidarity protests during 
TAC’s civil disobedience campaign against the government, which included demonstrations 
in front of South African embassies around the world (Mbali 2005: 36).23 
5.2 Legal and Organizational Interfaces: Disputes with Repercussions on the Global 
Level 
Legal interfaces are a key area which broadens or narrows people’s access to the public 
health system. The legal recognition of universal access to health as “a right of all and a duty 
of the State” by the 1988 Brazilian Constitution (Republic of Brazil 1988, Art. 196 in: Senado 
Federal 2003: 119) served as an important base in the negotiations with the World Bank, 
since the constitutional recognition implies the right of all citizens to health care, including 
treatment (Parker et al. 2001: 110). On the global level, Brazil’s fight for the designation of 
access antiretroviral treatment as a human right succeeded with the April 2001 Resolution of 
the UN Commission on Human Rights dealing with the “Access to medication in the context 
of pandemics such as HIV/AIDS.”24 In the run up to the decision, Brazil lobbied intensely for 
this resolution, beginning with its efforts to put free technology transfer and ARV price re-
ductions on the international agenda. Brazilian representatives secured the inclusion of the 
issue of ARV treatment and generics on the agendas of several international and multilateral 
organizations such as the Okinawa G8 Summit in July 2000, the Executive Committee of the 
WHO in January 2001, the UNCHR in February 2001, and the UNAIDS Board in April/May 
2001. As a consequence, the terrain was prepared for the great battle against the WTO panel 
moved in 2001 by the US government against Brazil’s patent law, as well as for the Doha 
Declaration in November 2001. 
The legal battle between Brazil and the United States over pharmaceutical patent rights had 
strong repercussions for both GHG and NHG. The association of the US pharmaceutical in-
dustry (PhRMA) had started to lobby against the Brazilian patent law, which excluded 
medical products from patent protection, as early as 1988 (Marques 2002: 43, Tachinardi 
1993: 67). Only after severe commercial sanctions had been undertaken in 1990, through pu-
nitive customs duties on selected Brazilian export products (Silva 2005: 131), did the Brazil-
ian government, in 1996, issue a revised patent law which included the protection of phar-
maceutical products. 
                                                     
23  In its campaign tactics, TAC has learnt from the US-based NGO AIDS Coalition to Unleash Power (ACT-UP) 
(Schneider 2001: 18). This provides further evidence of the strong interaction of NGO actors from the national 
and the global level through discoursive interfaces. 
24  The resolution was passed by a 52-0 vote with only one abstention (Wogart & Calcagnotto 2006: 96; Galvão 
2002: 219). One month later, the WHO World Health Assembly, following a Brazilian proposal, also con-
firmed “the right to health and that the progressive realisation of that right in the context of HIV/AIDS in-
volves access to treatment” (ISHR 2001). 
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However, the new Brazilian patent law still limited the scope of pharmaceutical patent 
rights. Paragraph 68 forced TNPCs to produce their drugs locally within three years of pat-
ent approval, with noncompliance allowing the government to issue compulsory licenses. 
The United States filed a complaint regarding this paragraph with the WTO in 2001 (Galvão 
2002: 216; Marques 2002: 44, 46). The dispute was only resolved when Brazil restricted the 
possibility of compulsory licensing to cases of a national health emergency. On June 25, 
2001, the United States withdrew its complaint. Brazil in turn agreed to notify the US gov-
ernment in advance if it found it necessary to issue a compulsory license. This solution also 
came as a result of open pressure from NGOs, simultaneously articulated through discour-
sive interfaces in the US and Brazil (Cepaluni 2005: 80-81; Ashraf 2001: 2112; Galvão 2002: 
215-216; Wogart/Calcagnotto 2006: 95-96). In short, through legal interfaces the United States 
were not able to strengthen the position of TNPCs, which would have blocked Brazil’s poli-
cies of providing universal access to treatment, producing generic ARVs, and negotiating 
prices for patented drugs—policies which have been referred to as the “Brazilian model” for 
AIDS treatment. In May 2007, Brazil issued its first compulsory license for an ARV. Under 
its terms, Brazil imports generic Efavirenz from drug companies other than the patent 
holder Merck (Nunn et al.: 12-13). 
Legal interfaces also led to significant confrontations in the South African context. The coun-
try came into the international limelight when the Pharmaceutical Manufacturers Associa-
tion of South Africa (PMA), backed by the American PhRMA, sued the South African gov-
ernment before South Africa’s High Court in 1997 for violating their IPRs.25 The lawsuit, 
which was based on the legal provisions of the TRIPS Agreement, was supported by the 
United States government, which threatened to impose trade restrictions on South Africa 
(Lanoszka 2003: 191-192). It targeted the Medicines and Related Substances Control 
Amendment Act, signed by President Mandela in December 1997, which gave the South Af-
rican minister of health the power to allow both compulsory licensing and parallel importa-
tion26 of patented medicines in general and of antiretroviral drugs in particular (Kühl 2002: 
76). Responding to intense national and international public pressure and with only a slim 
chance of winning the case, the 39 TNPCs represented by the PMA backtracked from the 
case in late 1998 (Weissman 2001). 
In January 2001 the lawsuit was reinstated. The chances for a victory on the part of the phar-
maceutical manufacturers were now considerably better, because South Africa was now 
obliged to fully comply with the requirements of the TRIPS Agreement (Kühl 2002: 76). The 
TNPCs maintained that the case was not directed against South Africa’s efforts to seek price 
reductions for antiretroviral medicine. That, however, was exactly the impression that AIDS 
                                                     
25  Extensive documentation of the case can be found on the web page of the American NGO CPtech, 
www.cptech.org/ip/health/sa/. 
26  “Parallel importation refers to the import of goods purchased in a foreign market by an independent third 
party and later resold in the domestic market where much lower prices compete with the prices charged by 
authorized distributors” (Kühl 2002: 18). 
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activists and NGOs in South Africa and around the world tried to create. Internationally rec-
ognized NGOs such as Médecins Sans Frontières, Oxfam, CPtech or ACT-UP pressured 
TNPCs to withdraw the case. Even the Bush administration now refrained from openly sup-
porting the pharmaceutical industry (Weissman 2001). Demonstrations were organized not 
only in South Africa, but also in front of several TNPCs’ headquarters in Europe and North 
America. The pharmaceutical industry, fearing another public relations nightmare, withdrew 
the lawsuit in mid-April 2001 (Lanoszka 2003: 192) and agreed to “a settlement almost on the 
government of South Africa’s terms. The only concession made by the government was to 
comply with decisions made by the World Trade Organization on TRIPS” (Kühl 2002: 78).27 
On balance, the legal interfaces developed through the High Court case have been an impor-
tant route for interaction between South African actors and the global level. The court case 
strengthened the South African government’s case for blaming the TNPCs and augmented 
the international pressure to reduce the prices of antiretroviral drugs. It is in the case of legal 
interfaces that the strategies of the Brazilian and the South African governments have shown 
the greatest similarity. Both governments fought against TNPCs as being responsible for 
high ARV prices and promoted the human right to access to essential medicines. According 
to Gauri and Lieberman (2004: 27), both countries “have styled themselves as emboldened 
leaders of the developing countries in this regard.” 
Closely related to the legal interfaces are the organizational interfaces, the use of which acts 
as a crucial indicator for the degree of cooperation between the national and the global level 
of health governance. Once more, while Brazilian policy makers had made extensive use of 
those opportunities even before the threat of AIDS required some degree of organizational 
interface, South Africa’s use of organizational links had been much more restrained, an ap-
proach which became even more isolationist during the AIDS crisis in the 1990s. 
Since the 1970s, the WHO has developed multiple initiatives with Brazilian health authori-
ties and academic institutions through its regional representative, the Pan American Health 
Organization (PAHO). These joint activities laid the conceptual basis for the reform of the 
Brazilian health system in the 1980s and 1990s. That in turn shaped the Brazilian BHAP 
(Lima 2002: 92-93; Fontes 1999: 113-114). With respect to the BHAP, the nature of these or-
ganizational interfaces was not always without conflicts. There were at times divergent con-
ceptions about the mode of resource-transfer interfaces (“authoritatively” earmarked re-
source allocations) and global and national policies and strategies in the field of HIV/AIDS, 
particularly prevention programs such as harm reduction and public campaigns. In the early 
1990s, this dissent led to a cessation of resource transfers (mainly knowledge) from WHO to 
Brazil and other countries such as Chile, Mexico, and Paraguay. Disagreement about the 
                                                     
27  As a consequence the Medicines and Related Substances Control Amendment Act from 1997 remained 
largely unchanged. While the Doha Declaration explicitly permits countries to issue compulsory licenses in 
the case of national health emergencies, the government rejected proposals from civil society to declare the 
HIV/AIDS epidemic a national emergency (Gauri & Lieberman 2004: 26). 
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fundamentals of the Brazilian response widened dramatically in 1991, when the government 
began the free distribution of AZT, and more so in 1992, with the initial negotiations for a 
strategic loan from the World Bank. At that point, the dissent had turned mainly towards 
the WHO headquarters in Geneva, an adversary which “opposed the Brazilian strategy in 
all international fora.” In the interaction between the Brazilian government and the WHO, 
the dissent along discoursive lines also decisively hindered the development of positive 
synergies along organizational interfaces. This dissent only lessened in 2002/3, as the 
WHO—with some influence from the Brazilian government—redirected its focus to an inte-
grated treatment-prevention approach and underlined the significance of BHAP as a model 
for emerging and developing countries (Teixeira 2005: 8-9). In 2003/4, Paulo Teixeira, 
formerly director of the Brazilian STD/AIDS Programme, was appointed director of the 
HIV/AIDS Department of the WHO, which also indicates the rising Brazilian influence on 
that particular organization. 
The UNAIDS Theme Group on HIV/AIDS, established in Brazil in 1997, includes seven UN 
system agencies and, in its “expanded group,” also two Brazilian ministries (Health/BHAP 
and Foreign Affairs); three international organizations (FAO, ILO, and UNIFEM); two bilat-
eral donor organizations (GTZ and USAID); the global NGO Family Health International; 
and two representatives from civil society (UNAIDS 2001: 3). With this multilateral compo-
sition, the Theme Group has been able to articulate the activities of international organiza-
tions in the country with national actors and so to mobilize organizational and, since 2001, 
programmatic support for the Brazilian HIV/AIDS policy. According to Paulo Teixeira, the 
UNAIDS Theme Group in Brazil brought about “positive synergic effects” at federal, state 
and municipal levels of government (Interview, Teixeira, 24.8.2004), mainly through its sup-
port for implementation of the “Three Ones Principles”: one national AIDS coordinating au-
thority, one agreed AIDS action framework, and one agreed country-level monitoring and 
evaluation system. It has decisively influenced the organization of the Brazilian HIV/AIDS 
prevention campaigns, for instance, by motivating local mayors to actively participate and 
inform their communities about the epidemic during the Red Ribbon Campaign and others 
(Interview, Milhomem, 15.9.2004). 
Conversely, Brazilian actors have also effectively used organizational interfaces to influence 
GHG. In 2004, Brazil’s representative was unanimously elected vice-president of the 
UNAIDS Program coordinating board, and in 2005 he assumed the presidency of the body 
(CNAIDS 2004). This exemplifies the government’s general policy of actively working on 
HIV/AIDS in international organizations. There is also evidence that Brazil’s civil society has 
exerted some influence on GHG. ABIA, for instance, was actively involved in the 5th Inter-
national AIDS Conference in Montreal in 1989 (Galvão 2000: 87). On that occasion, the Inter-
national Council of AIDS Service Organizations (ICASO) was established with the main aim 
of strengthening the global response of civil society organizations. Acting as the ICASO Se-
cretariat for Latin America, ABIA also spearheaded the creation of the Latin American and 
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Caribbean Council of AIDS Service Organizations (LACCASO) as a further organizational 
interface (Galvão 2000: 87).28 
While the South African government has rarely engaged in organizational interfaces concern-
ing the treatment of HIV/AIDS, there have been several organizational interfaces in the pre-
vention area. One of those has been the LoveLife public-private partnership, an organization 
working in the field of HIV/AIDS prevention. Co-financed by the US-based Kaiser Family 
Foundation and other donors together with the South African government, which provided 
34 percent of the overall budget, LoveLife has also received substantial resources from the 
Global Fund.29 Running South Africa’s biggest HIV/AIDS prevention program for teenagers, 
it has designed accessible and youth friendly clinics and advertising campaigns and has 
sponsored various events (Interview, O’Connor, 11.05.2005). LoveLife enjoys a cordial and 
collaborative relationship with the government and even has the minister of health on its ad-
visory board. In short, it has acted as a “government service-provider” (Mbali 2005: 18). 
There is also some evidence that experts from the Clinton Foundation were involved in the 
Joint Health and Treasury Task Team (JHTTT), which was set up to investigate the feasibil-
ity and the costs of universal access to treatment for HIV/AIDS in South Africa in 2002 
(Ijumba et al. 2004: 333). The US foundation was thus linked to the national level through an 
organizational interface. Yet, although the Clinton Foundation was—on the global level—
very influential in reducing prices for antiretroviral drugs, their experts were later denied 
further access to South African institutions, with the government stopping any further coop-
eration with the foundation. 
Table 3 provides a synopsis of the comparison between the Brazilian and the South African 
cases, focusing on the different types of interfaces involved. Resource-based interfaces re-
garding material (service and financial) exchanges turned out to be powerful as expected 
and favored the early development of the Brazilian treatment program. The intensive links 
between resource-based and discoursive interfaces, however, are highly important for ex-
plaining the role of Brazil as a forerunner in the access politics of developing countries and 
as a state ally of the CSOs’ access campaign. 
                                                     
28  In Galvão (2000), further examples of Brazilian NGOs entering into organizational interfaces can be found. 
29  It is thus also an example of the resource-based interface. The organization’s annual budget for 2005 was ap-
proximately R200 million (Mail & Guardian 2005a). In 2005, the Global Fund abruptly ceased financial sup-
port to the prevention program, citing LoveLife’s missing performance indicators as the prime reason (Mail & 
Guardian 2005b). 
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Table 3: Fighting HIV/Aids: Major Interfaces of Brazilian and South African NHG 
Interfaces Brazil South Africa 
Civil society and public health sector substantially sup-
ported by global institutions and NGOs since 1980s. 
Civil society supported by global institu-
tions and NGOs since 1980s, but decisively 
only since 1990s. 
Resource-
based 
Heavy reliance on foreign financing for public health in 
1980s and 1990s (debt crisis; public health free of 
charge), incl. state and federal HIV/AIDS programs 
(since 1983). 
Government’s health budget not con-
strained by high indebtedness. Significant 
global financing for government programs 
only since 2000, treatment programs since 
2003. 
Since the 1980s civil society’s human rights discourse for 
integrated prevention-treatment approach (dialogue be-
tween national and global NGOs and all levels of gov-
ernment).  
Since the 1980s civil society’s human rights 
discourse for integrated prevention-
treatment approach has been developed 
through dialogue between national and 
global NGOs. 
Discoursive 
Early responsiveness of states (since 1983) and, progres-
sively, federal government (since 1985, except 1990–
1992) to civil society pressure for the integrated preven-
tion-treatment approach. 
Late (since 2003) responsiveness of most 
provincial governments and of national 
government to civil society pressure for in-
tegrated prevention-treatment approach. 
Legal Constitutional provisions (1988) for universal public 
health system as foundation for the Brazilian HIV/AIDS 
program BHAP. 
Government has resisted US pressure against patent 
policy (since late 1980s) and pressed TNPCs on pricing 
of ARVs in Brazil (2001–2007) based on Act 9313/Nov. 
1996, for free-of-charge ARV distribution, and Patent 
Act Nr. 9279/14.5.1996, allowing compulsory licensing in 
certain cases. 
Medicines and Related Substances Control 
Amendment Act of Dec. 1997 (allowing 
compulsory licensing and parallel impor-
tation of patented drugs, based on TRIPS). 
Was the main issue of TNPCs’ lawsuit of 
1998/ 2001. 
Explicit government commitment to com-
ply with WTO rules as compromise in le-
gal conflict with TNPCs (2001). Despite its 
provisions, the act has not been used for 
compulsory licensing and parallel impor-
tation of drugs.  
Brazilian government fought successfully for recogni-
tion of AIDS treatment as a human right at UNCHR and 
WHO (2001). 
Spearheading of developing countries’ fight for the 
safety of using TRIPS flexibilities (WTO/Doha negotia-
tions 2001) and generally to facilitate compulsory licensing 
and parallel imports of essential medicines.  
Government fought to use TRIPS flexibil-
ities in WTO/Doha negotiations 2001 to-
gether with Brazil and 50 other developing 
countries. 
Organizational 
Cooperation with WHO since 1970 on health reform and 
the unified public health system, but dissent over 
HIV/AIDS-treatment approach since the 1980s; coopera-
tion (government/NGOs) with UNAIDS Theme Group 
in prevention campaigns since 1997. 
Intense use of global organizational channels by gov-
ernment to influence UNAIDS approach to HIV/AIDS 
treatment. 
Active participation of Brazilian NGOs in developing in-
ternational and Latin American cooperation among 
HIV/AIDS NGOs. 
Little organizational cooperation by South 
African government concerning treatment 
of HIV/AIDS, at least until 2003. 
Refusal of national government to cooper-
ate with Clinton Foundation for universal 
access to HIV/AIDS treatment after pre-
liminary studies in 2002. 
Organizational interface hardly used by 
government to influence global level. 
Until recently, PPP cooperation only con-
cerning HIV/AIDS prevention (e.g., 
LoveLife). 
Source: Authors’ compilation. 
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6 Conclusions 
The examination of the fight against AIDS and the confrontation over ARV prices between 
Brazilian and South African government representatives, supported by local and global civil 
society groups, and the TNPCs and government agencies of the North reveals a number of 
points which could be important for future policy decisions. 
• First, the seemingly all-powerful transnational corporations were forced to negotiate and 
retreat vis-à-vis two developing countries in view of a global health crisis. While the im-
portance of the NGOs’ involvement is undeniable and has been cited here and else-
where, the emergence of strong national health governance in Brazil and the successful 
opposition of both Brazil and South Africa to a narrow, TNPC-oriented interpretation of 
the TRIPS Agreement were crucial examples for other developing countries to also de-
fend their own interests in GHG in a more self-assertive manner. At the same time, the 
successful stance of CSOs against the South African government points to the strength of 
global civil society in the case of health issues and to the fact that conflicts on access to 
medicines are not fought along ideologically hardened North-South lines alone.30 
• Second, these accomplishments were achieved through the artful use of different inter-
faces, the combination of which made the change possible. Important as it was as a first 
step, defending presumed “national interests” along legal interfaces was a necessary but 
not sufficient condition for changing the rules and regulations of GHG; change was ul-
timately accomplished by using opportunities and reacting to challenges along resource-
based, organizational, and especially discoursive interfaces in the multilevel global pol-
ity. As a consequence, future developments in NHG and GHG will require policy mak-
ers to consider using the multiplicity of interfaces in order to achieve comprehensive so-
lutions to global health issues. 
• Third, it is impossible to clearly separate the various interfaces utilized during the pro-
tracted conflict, but each played a prominent part at some stage of the multiple negotia-
tions between 1995 and 2008. 
‒ TRIPS, the legal interfaces in the South African courts, and the agreements negotiated 
in Geneva played a crucial role in supporting Brazil’s legal battles and its claims for 
access to low-cost medicines. 
‒ The increasing global involvement in the fight against HIV/AIDS permitted Brazil to 
fully engage in a number of organizational interfaces, which helped not only that 
country but also other emerging economies sort out their concerns and push the 
countries of the North to reconsider their positions concerning global health issues. 
‒ Resource-based interfaces played a different role in each country. Once convinced to 
make the fight against the pandemic a top priority, the Brazilian federal government 
                                                     
30 In that context it is interesting to note the substantial amount of US financial support for AIDS programs 
(PEPFAR) and the meetings President Bush had with Brazilian president Lula to help fight AIDS in Africa. 
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was in a position to negotiate the terms of cooperation with major financial donors 
and creditors. In contrast, South Africa’s financial independence and the govern-
ment’s specific stance with respect to the treatment of HIV/AIDS helped it to deter-
mine its health policies independently—alas, at a high price. 
‒ Accomplishments at the negotiating tables were strongly supported by discoursive 
power, which was first used successfully by civil society at all levels but which gov-
ernment representatives and the TNPCs also increasingly engaged in. The number of 
papers and reports issued by the industry’s national and international associations, 
some of them written by international think tanks, signaled an increased willingness 
to enter into discoursive interfaces on a quasi-academic level. 
• Fourth, the rapid response of the TNPCs represents a move into a new round of confron-
tation which will challenge the participants to further engage in multiple interfaces. Re-
newed “forum shifting” by major Northern countries away from the multilateral stage 
and increased attention to bilateral trade treaties containing TRIPs+ clauses has been an-
swered by the South’s introduction of a “development agenda” within WIPO and its 
proposal for a “Global Framework on Essential Health Research and Development” at 
the World Health Assembly of May 2006. This, in turn, has led to the establishment of 
the Intergovernmental Working Group on Public Health, Innovation and Intellectual 
Property, which aims to develop an international agreement on these questions. 
This new round of negotiations on concepts for the funding of health research on the one 
hand and the evolving norm of “universal access to essential medicines” on the other indi-
cates the emergence of new institutional forms in GHG. Certainly, intergovernmental 
agreements continue to play an important role in the establishment of binding rules. Never-
theless, state actors are also becoming part of a more open field of global politics in which 
various types of non-state actors (CSOs, TNCs, PPPs, philanthropic foundations) are 
strengthening their positions and creating a complex field of interfaces. Private companies 
and CSOs are now playing a more apparent role in pushing for legal agreements, amend-
ments, or authoritative interpretations of existing rules, as has been analyzed with respect to 
the conflicts around TRIPS. In some GHG institutions, such as GFATM and PPPs, private ac-
tors have voting rights and are playing an important role as experts—as well as strong ad-
vocative actors and lobbyists for their own interests. 
Eventually, a new and enlarged set of legal norms should emerge from the organizational, 
financial, and discoursive interfaces described above. That in itself should simplify and clar-
ify the roles of the various actors in the changing field of global health. As described earlier 
in this paper, the first steps in that direction have been undertaken; they are waiting to be 
supplemented and coordinated through further agreements on the emergence of an im-
proved GHG. 
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